Saturday, December 7, 2002

ASH 2002

OncoLink attended the 44th Annual Meeting of the American Society of Hematology (ASH) from Philadelphia, Pennsylvania. OncoLink reporters provided in-depth, up-to-the-minute coverage of sessions and presentations.

Reading Terminal Market
Historic Reading Terminal Market Pennsylvania Convention Center


Bexxar Radioimmunotherapy Produces a Substantial Number of Durable Complete Responses in Patients with Multiply Relapsed or Refractory Low Grade or Transformed Low Grade Non-Hodgkin's Lymphoma Duration of Molecular Remission in Patients with Acute Promyelocytic Leukemia (APML) Treated Primarily with Arsenic Tri-oxide High Response Rates and Durable Remissions in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma Treated with Tositumomab and Iodine I-131 Tositumomab (Bexxar) Intermediate Dose Melphalan for de novo Multiple Myeloma gives high complete response rate and durable long term survival Long Term Follow Up of a Phase II study of Rituximab in Combination with CHOP Chemotherapy in Patients with Previously Untreated Aggressive Non-Hodgkins Lymphoma (NHL) Oral Fludarabine phosphate as first-line treatment of chronic lymphocytic leukemia Phase I-II study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia Preliminary Report of a Phase II Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarag)Given in Combination with Cytarabine in Patients with Acute Myelogenous Leukemia Prevalence and Management of Anemia in Patients with Hematologic Malignancies and Solid Tumors: Results from the European Cancer Anemia Survey (ECAS) Quality of Life, Blood Transfusions, and Toxicity, in Anemic Patients with Advanced Cancer Receiving Weekly Erythropoietin While on Chemotherapy: Results from a Phase III Randomized Double-Blind Placebo-Controlled Study. Rituximab Treatment Failures: Tositumomab and Iodine I-131 Tositumomab (Bexxar) Can Produce Meaningful Durable Responses Zevalin Radioimmunotherapy is Not Associated with an Increased Incidence of Secondary Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML)

Keywords

Click on any of these terms for more related articles

Blogs

Cancer and Hair Loss
by Bob Riter
February 11, 2016